$A

Dolsten Mikael sold $96K of A

Dolsten Mikael sold 634 shares of AGILENT TECHNOLOGIES, INC. (A) at $151.38 on 2026-09-04.

Original reporting
SEC EDGAR · Dolsten Mikael
Published Sep 9, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$A
Neutral
high confidence
Mentioned
$A
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANeutralLow
01

Why it matters

The sale is routine and unlikely to affect Agilent's stock price.

02

Market read

Minor insider sell; limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-09

Background

Form 4 filings disclose insider transactions; traders monitor for material changes.

Company-level read

Ticker impact

$ANeutralHigh confidence
Context

Director Dolsten Mikael sold 634 shares of Agilent Technologies for $95,972 on 2026-09-04, reducing his holding to 4,924 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The transaction size is small relative to market cap and typical insider activity.

Market effects

None

None

None

Counterpoint

Insider sell could signal concerns, but size is too small to act on.

Key entities

  • Agilent Technologies, Inc.

    US-listed provider of life sciences and diagnostics equipment.

  • Dolsten Mikael

    Director of Agilent Technologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMedAI 9/10

Agilent completes acquisition of Proscia for $240 million

Agilent Technologies (NYSE:A) completed its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash, with up to $30 million in additional payments tied to future performance milestones. Proscia is now part of Agilent’s Life Sciences and Diagnostics Markets Group. The acquisition adds a recurring-revenue software business to Agilent’s pathology portfolio. Agilent generated $6.95 billion in revenue in fiscal year 2025.

$AHighAI 8/10

Software for examining tissue, trusted by 16 of the top 20 drug companies, now belongs to Agilent.

Agilent Technologies (A) completed the acquisition of Proscia, a digital pathology platform trusted by 16 of the top 20 drug companies. The deal expands Agilent’s pathology portfolio, adding a recurring-revenue software business and enhancing its AI-enabled pathology workflows. Proscia’s platform has FDA 510(k) clearance for primary diagnosis and supports clinical diagnostics, biopharma, and life-sciences research.

$AHighAI 9/10

Philadelphia's Proscia to Sell to Agilent for Up to $270M

Agilent Technologies (NYSE: A) agreed to acquire Proscia, a digital pathology software company, for up to $270M. The deal includes $240M upfront and $30M in performance-based payments. Proscia's software integrates AI tools and manages digital tissue images, serving over 4,000 labs and 16 top pharmaceutical firms. The acquisition aims to expand Agilent's presence in the $5B pathology market, combining its diagnostic instruments with Proscia's software.

$AHighAI 9/10

Philadelphia AI Cancer Diagnostics Firm Proscia Acquired for Up to $270M

Agilent Technologies (A) is acquiring Proscia, an AI cancer diagnostics firm, for up to $270M ($240M in cash, $30M in milestones). Proscia's software digitizes tissue samples for AI analysis, used by 4,000 labs and 16 top pharma companies. The deal expands Agilent's presence in digital pathology. Proscia will remain in Philadelphia, with the deal expected to close in early fiscal 2027.

$AHighAI 9/10

Agilent Agrees to Buy Proscia for $240M

Agilent Technologies agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. Proscia's trailing revenue exceeded $18M. The deal will integrate Proscia's digital pathology software into Agilent's business, expected to close in early fiscal 2027.

$BMBLHighAI 9/10

Deal Dispatch: Ithaca Holdings Buys Bumble for $1.3B, The Knot Acquires Zola, Character.ai Bankruptcy

Bumble (BMBL) agreed to a $1.3B all-cash acquisition by Ithaca Holdings, becoming privately held. IonQ will acquire Elisity in an all-stock deal up to $1.3B. Agilent (A) to buy Proscia for $240M. Workday (WDAY) acquiring C1.ai. Aurora Cannabis exploring alternatives to Curaleaf's bid. Character.ai filed for bankruptcy, Disney to pay $20M for IP. Getty Images plans Chapter 11, going private with Koch backing.